ReviewCurrent oncology reports2026
Harnessing Proteogenomics to Advance Precision Oncology: From Melanoma and Hepatocellular Carcinoma Perspective.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewGenomic profiling has significantly advanced precision oncology; however, relying solely on genome-driven approaches is often insufficient to capture the full molecular complexity of cancer. Proteogenomics integrates proteomics, transcriptomics, and genomic analyses to provide a more holistic view of tumor biology by revealing how genetic alterations translate into functional consequences at the protein level. RECENT
findingsThis multidimensional framework enhances the ability to identify clinically actionable biomarkers, uncover dysregulated pathways, and understand tumor heterogeneity with greater precision. By advancing tumor molecular profiling, proteogenomics offers the potential to refine tumor classification, improve diagnostic accuracy, and better tailor therapeutic strategies to individual patient needs. This review examines the expanding role of proteogenomics as an essential tool in personalized cancer management. Key analytical platforms, including mass spectrometry–based proteomics and phosphoproteomics, next-generation sequencing, and integrative computational pipelines, are discussed. We also highlight illustrative applications across diverse malignancies, including melanoma and hepatocarcinoma (HCC), where proteogenomic insights have informed therapeutic decision-making, revealed novel drug targets, and improved understanding of treatment resistance mechanisms; challenges and future prospects were also discussed. These advancements collectively highlight the increasing significance of proteogenomics in the evolution of precision oncology and the centrality of integrated molecular profiling in personalized cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.